Abstract: The invention relates to a method for manufacturing a turbine shroud (24) for a turbomachine, the method comprising manufacturing at least one turbine shroud sector (28), positioning the turbine shroud sector (26) in a bottom mold so that an outer surface of the turbine shroud sector is in contact at least in part with the bottom mold, and depositing a powder layer on an inner surface (28) of the turbine shroud sector (26). Thereafter, a top mold is positioned on the powder layer and an abradable layer (32) is made by subjecting the powder layer to a method of SPS sintering, the abradable layer (32) being for being disposed facing a turbine wheel.

Abstract: A method for manufacturing microcapsules containing an active substance, the method including: providing an aqueous solution of a surfactant, an oily phase comprising the active substance and a first monomer, and a polar phase comprising a second monomer; preparing an oil-in-water emulsion by adding the oily phase to the aqueous solution of the surfactant; adding the polar phase to the oil-in-water emulsion, in order to obtain a polymer in a reaction mixture, by polymerization of the first monomer and the second monomer; isolating the microcapsules, including a wall formed by the polymer and containing the active substance, from the reaction mixture; wherein the polymer is a poly(beta-amino ester). Microcapsules obtained by the method.

Abstract: A method for determining a rate of sedimentation or of creaming of a mixture in suspension, including an application of a sample of the mixture in suspension to a photonic microresonator, an application of a first optical signal at the input of the photonic microresonator carrying the sample of the mixture in suspension, an acquisition and a recording of a second optical signal, delivered at the output of the microresonator carrying the sample of the mixture in suspension, and a determination of information representing a rate of sedimentation or of creaming of the mixture from the recorded second signal, by successive iterations of spectral analysis of the second optical signal.

Abstract: The present invention relates to a method of interpreting different antibiogram images in which it is possible to recognize a phenotype of bacterial resistance relative to antibiotics by comparing photographs using a photographic image bank of the reference antibiogram without any need to interpret them using the EUCAST or CA-SFM interpretation data; providing that for a given phenotype, there is available a collection of photographs of a plurality of bacteria of the same species and of the same phenotype.

Abstract: The invention relates to the use of an extract of Sextonia rubra or the constituents thereof, rubrenolide and/or rubrynolide, as an insecticide agent against mosquitoes, especially as a larvicide agent.

Abstract: Disclosed is an ankle ergometer for measuring a force exerted on a user's ankle joint by muscles involved in ankle mobility, including: a first splint-type portion receiving the lower limb when the user's knee is extended, and including a lower limb immobilizer with the leg in extension, and a second portion including: a) a main body attached to the first portion, b) a counter-supporting unit secured to the main body, c) a rigid plate forming a supporting surface for the lower surface of the foot, the rigid plate being substantially static relative to the counter-supporting unit, d) a force sensor between the plate and the counter-supporting unit, the plate not being secured to the main body so the sensor measures the force exerted on the supporting surface of the plate by the ankle mobility muscles, the force being transmitted from the plate to the counter-supporting unit.

Abstract: Disclosed is a reactive filter, that is a selective catalytic reduction filter or an oxidative reaction filter, including a porous substrate including internal pores having their inner surface, totally or partially, directly coated with a catalytic zeolite material resulting from an in situ hydrothermal synthesis. Also disclosed is a process for preparing such a reactive filter and the use thereof in an engine exhaust depolluting system.

Abstract: A method and a system for laser pulse wavefront correction and focusing optimization for laser Wakefield interaction to accelerate electrons to high energy, and more generally for laser matter interaction where both far field and intermediate field optimization are important, allowing a robust wavefront correction and focusing optimization with a high-power laser system at its nominal laser pulse energy and laser pulse duration. The method comprises, after laser beam focusing by focusing optics, coupling an imaging unit to a wavefront sensor, thereby measuring the laser beam wavefront, and adjusting the measured laser beam wavefront to converge to a reference wavefront of the imaging unit using a spatial phase-modifying device.

Abstract: The invention is in the field of therapy of gut inflammatory diseases such as Inflammatory Bowel Diseases (IBD) or Irritable Bowel Syndrome (IBS) including Gluten hypersensitivity. The inventors showed that ELA2A secreted by epithelial cells in the extracellular space is over-expressed in IBD conditions degrading tight junction proteins and controlling cytokines expression. Overexpression of ELA2A conferred a pro-inflammatory phenotype both in cell expression systems and in vivo in animal model of IBD. The inventors also showed that ELA2 over-expressing intestinal epithelial cells increase the release of CXCL8 protein compared to control cells. The increased CXCL-8 protein release observed in cells overexpressing ELA2A is inhibited by ELAFIN addition to the culture, in a dose-dependent manner. In particular, the invention relates to inhibitors of Elastase ELA2A, for use in the treatment of Inflammatory Bowel Diseases, such as Crohn's Disease, Ulcerative Colitis, Celiac disease, and Pouchitis.

Abstract: The invention relates to a curable resin that represents an excellent substitute for phenolic resins and is therefore able to replace phenolic resins in all applications in which they are used. Said resin is characterised in that it comprises: (1) at least one prepolymer resulting from the prepolymerisation of a compound A comprising at least one aromatic or heteroaromatic ring, a first group —O—CH2-C?CH and at least one second group selected from the groups —O—CH2-C?CH2 and —CH2-CH?CH2, said groups being carried by the at least one aromatic or heteroaromatic ring; and (2) a compound B comprising at least two thiol groups (—SH). The invention also relates to a material obtained by curing said curable resin, and in particular to an ablative composite material. The invention further relates to a material obtained by curing said curable resin.

Abstract: The present invention relates to the cosmetic or pharmaceutical use for a composition comprising a salicylic or nicotinic acid derivative inhibiting chemokines, for preventing or treating chronic internal and/or external inflammatory conditions.

Abstract: A proton-conductive electrochemical device and method for manufacturing the device. The device comprising a positive electrode able to reduce an oxidizing species, a negative electrode able to oxidize a reducing species, and a proton-conductive electrolyte, in contact with the positive and negative electrode. The device further comprises a layer able to diffuse protons and electrons, and forms a protective barrier against contaminants for the electrolyte. The layer is in contact with both the electrolyte and the negative electrode, and comprises a material of the type ABB?O3 or a material of the type ABO3, wherein A is an element chosen from group II of the periodic table, B is an element chosen from cerium and group IVB of the periodic table, B? is an element chosen from lanthanides or group VIIIB of the periodic table, and the layer has a porosity of less than 10% by volume.

Abstract: Provided herein is a method for determining the temporal progression of a biological phenomenon which may affect a studied subject, the method including the steps of providing first data relative to biomarkers for the studied subject, the biomarkers being relative to the progression of the biological phenomenon, providing a numerical model, converting the first data into at least one point on the same Riemann manifold, and using a numerical model to determine a temporal progression for the biological phenomenon for the studied subject, the numerical model being a function in a Riemann manifold, the numerical model associating to values of biomarkers a temporal progression trajectory for the biological phenomenon and data relative to the dispersion of the progression trajectory for the biological phenomenon among a plurality of subjects, the numerical model being obtained by using a stochastic approximation in an expectation-maximization technique on data relative to biomarkers.

Abstract: The present invention relates to a process for preparing a polymer/biological entities alloy, comprising a step of mixing a polymer and biological entities that degrade it, during a heat treatment, said heat treatment being performed at a temperature T above room temperature and said biological entities being resistant to said temperature T, characterized in that said biological entities are chosen from enzymes that degrade said polymer and microorganisms that degrade said polymer.

Abstract: Disclosed is a medico-surgical simulator and to a corresponding method. The medico-surgical simulator includes a vascularization device and/or a ventilation device, as well as a regulation device. The medico-surgical simulator is arranged so as to be connected to a cadaver and to vascularize an arterial system of the cadaver via the vascularization device and/or to ventilate a respiratory system of the cadaver via the ventilation device. The regulation device controls the vascularization and ventilation devices in such a way as to simulate cardiorespiratory functions for providing surgical training carried out on the cadaver with a very high degree of realism.

Abstract: The present invention concerns a method for sequencing oligosaccharides, which makes it possible to identify the primary sequence of an oligosaccharide of unknown structure, including its monosaccharide composition, the position (regiochemistry) and configuration (stereochemistry) of glycosidic bonds, the nature and position of functional modifications, and its branched structure, particularly including the identification of the reducing end.

Abstract: The invention relates to a method for automatic and continuous measurement of a sedation state of a patient in an intensive care unit. The method according to the invention comprises the following steps: providing signals representative of the condition of the patient, said signals comprising cardio-circulatory signals, signals representative of the respiratory activity and signals representative of the motor activity of the patient; and determining a global index representative of the sedation state of the patient.

Abstract: In a method and magnetic resonance (MR) apparatus for MR image reconstruction, an image reconstruction algorithm is used that operates on one calibration matrix that is formed by reorganizing a number of individual, undersampled k-space data sets respectively acquired by multiple reception coils in a parallel MR data acquisition from a subject exhibiting motion. The motion causes the k-space data sets to exhibit errors. In order to use the calibration matrix in the reconstruction algorithm, it is subjected to an iterative rank reduction procedure in which, in each iteration, a residual is calculated for each data point that represents how poorly, due to motion-induced corruptions, that data point satisfies the low rank constraint, and non-satisfying data points are removed from the data point for the next iteration. The resulting low rank matrix at the end of the iterations is then used to produce images with fewer motion-induced errors.

Abstract: The present disclosure relates to an inhibitor of Dynamin 2 or composition comprising the same for use in the treatment of Duchenne's muscular dystrophy.

Abstract: The present invention relates to the use of a DBait molecules by systemic routes without any combination with an endosomolytic agent.